Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Survodutide Pre-filled Syringe vs Vial in Healthy and Overweight/Obese Participants
NCT07768813Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of survodutide in obesity (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point, Maximum measured concentration of the analyte in plasma and 1 more. Started Sep 2026; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07768813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07768813.